Next Article in Journal
Zebrafish as an In Vivo Model to Assess Epigenetic Effects of Ionizing Radiation
Next Article in Special Issue
Contribution of Gray and White Matter Abnormalities to Cognitive Impairment in Multiple Sclerosis
Previous Article in Journal
Differential Impacts of Alternative Splicing Networks on Apoptosis
Previous Article in Special Issue
Prolactin: Friend or Foe in Central Nervous System Autoimmune Inflammation?
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(12), 2106;

Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?

Department of Neurology, Hannover Medical School, 30625 Hannover, Germany
Private Ophthalmology Office, 30851 Langenhagen, Germany
Department of Ophthalmology, Hannover Medical School, 30625 Hannover, Germany
Department of Neurology, University of Duisburg-Essen, 45147 Essen, Germany
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Academic Editor: Sven Meuth
Received: 29 July 2016 / Accepted: 7 December 2016 / Published: 14 December 2016
(This article belongs to the Special Issue Advances in Multiple Sclerosis 2016)
Full-Text   |   PDF [18937 KB, uploaded 14 December 2016]   |  


Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing–remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provide a detailed review about fingolimod associated macular edema (FAME), its current incidence with or without diabetes mellitus, and previous therapy attempts and outcomes in MS patients. Intravitreal administration of antibodies raised against vascular endothelial growth factor A (VEGF-A) has not yet been used in the management of FAME, however, the excellent therapeutic response in our patient may justify the use of anti-VEGF-A agents in combination with cessation of fingolimod to achieve fast resolution of FAME and to prevent visual deficits, particularly in bilateral FAME. View Full-Text
Keywords: multiple sclerosis; fingolimod; macular edema; VEGF; diabetes mellitus multiple sclerosis; fingolimod; macular edema; VEGF; diabetes mellitus

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pul, R.; Osmanovic, A.; Schmalstieg, H.; Pielen, A.; Pars, K.; Schwenkenbecher, P.; Sühs, K.W.; Yildiz, Ö.; Frank, B.; Stangel, M.; Skripuletz, T. Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See? Int. J. Mol. Sci. 2016, 17, 2106.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top